Feedback PLC (LON:FDBK)

Feedback PLC (LON:FDBK)


Share Price
0.90 p
Change
0.175 (24.14 %)
Market Cap
£3.36 m
Proactive Investors - Run By Investors For Investors

Feedback PLC

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through our trading subsidiary, Feedback Medical Limited.

Their products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, such as cancer. Feedback Medical work with customers globally...

EPIC: FDBK
Market: LSE:FDBK
52-week High/Low: 2.49p / 0.63p
Sector: Electronic & Electrical Equipment [T3]
Market Cap: £3.36 m
Website: www.fbk.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Feedback PLC


Feedback PLC Snapshot

Our proprietary technologies are TexRAD and Cadran. TexRAD is a patent-protected software tool which extracts and quantifies texture features in radiological images, assisting research into all tumour types. In the exciting new field of radiomics, TexRAD uncovers biomarkers in medical images which are invisible to the naked eye.

TexRAD has featured in over 100 academic publications, won numerous awards and is currently used in over 50 prestigious institutions worldwide. We have recently launched TexRAD Lung for analysis of lung cancer which is certified for clinical use and is CE marked for use in the EU.

The Cadran image platform provides hospitals and research institutes with a comprehensive picture archiving communication system (PACS) for medical images. It equips users with a flexible, convenient and secure platform for image handling from all imaging modalities, such as CT and PET scanners. Cadran Viewer is certified for clinical use and is CE marked for use in the EU.

Our History

APRIL 2018 - INNOVATION IN IMAGING
Cambridge Computed Imaging and TexRAD, companies of the Feedback plc group are restructured together as Feedback Medical Ltd. This is to better reflect the company vision to lead global innovation in medical imaging technology and to simplify the understanding of the TexRAD and Cadran product ranges.

NOVEMBER 2017 - TEXRAD ACHIEVES FIRST MEDICAL DEVICE
TexRAD Lung achieves a CE mark for clinical use in the EU. The software automatically quantifies texture of lung tumours using PET/CT images of the chest, giving lung cancer medical specialists information that is unique to individual patient tumours.

NOVEMBER 2016 - TEXRAD; A WEALTH OF OPPORTUNITIES
TexRAD Research continues to be adopted by world renowned research institutions across the globe. Academic publications indicate opportunities for TexRAD to benefit lung cancer care. This leads to a development programme for a TexRAD lung specific clinical product.

NOVEMBER 2014 - FOCUS ON MEDICAL IMAGING
Feedback moves into the growing field of medical imaging with the conditional acquisition of Cambridge Computed Imaging Ltd and TexRAD Ltd.

AUGUST 2013 - FEEDBACK PLC
Feedback plc, previously a company specialising in electrical engineering and instrumentation, is established as an AIM listed investment company.

FEBRUARY 2011 - TEXRAD LTD FOUNDED
The founders of TexRAD enter into a partnership with Cambridge Computed Imaging Ltd to form TexRAD Ltd. This is to help develop the TexRAD software to maximise its potential in radiomics and reach across the world.

AUGUST 2007 - FIRST TEXRAD ACADEMIC PUBLICATIONS
Researchers from Brighton and Sussex Medical School and the University of Sussex collaborate to develop TexRAD. The TexRAD algorithm successfully gains its first academic publications, with the possibility of applications into different disease states explored.

SEPTEMBER 2001 - CAMBRIDGE COMPUTED IMAGING FOUNDED
Cambridge Computed Imaging Ltd is founded and offers Cadran, the picture archiving communication system (PACS) for medical images. As a spin out from Royal Papworth hospital, the core technology aims to aid those within hospital radiology and cardiology departments.

 

Cadran

  • Medical imaging tools for decision support
  • Cadran Image Storage Management offers fully featured image display, review and manipulation options and enterprise archiving for clinical, non-clinical and teaching use
  • Medical images wherever and whenever you need them. Fully featured archive, robust and secure.

Cadran is produced by Cambridge Computed Imaging Ltd. CCI are specialists in providing software that helps doctors use medical images to make decisions.

Clinicians can display, review and manipulate images using in-line measurement and analysis tools to assist diagnosis and quantify treatment response.

 

For more information go to CadranISM.com

 

TexRAD

  • Stratification of clinical diagnostic images for prognosis, risk and treatment response
  • TexRAD analyses the textures in radiological scans and has the potential to assist clinicians in assessing the prognosis of patients with cancer. TexRAD analysis has been retrospectively performed on images from a wide range of conditions including colorectal, breast, lung, prostrate, oesophageal, head and neck, and renal cancers

TexRAD offers an innovative quantitative tool to clinicians researching the diagnosis, prognosis and treatment response of cancer.

TexRAD helps users analyse, detect and measure textures in medical images, revealing more information than is evident to the naked eye.

 

More information at TexRAD.com

 

Cambridgeshire.

Dr Tom Oakley, Chief Executive Officer

Dr Tom Oakley joins Feedback plc as Chief Executive Officer. Dr Oakley is a qualified radiologist with significant clinical and academic experience, he also holds a successful track record of entrepreneurial activity. This includes serving as Director of NHS services at Synergix Health, where he led the launch of telemedicine services to 40,000 patients. In 2016, he founded Innovation Doctor Ltd, aimed at exploring the digital healthcare space and supporting digital start-ups and SMEs. As Medical Director of 3D LifePrints, a medical 3D printing company, he has helped expand their services into 20 NHS trusts.

Dr Alastair Riddell, Non-Executive Chairman

Dr Riddell has over 30 years’ experience in the pharmaceutical, life science and biotech industries, with 18 years as a main board director. After 10 years directing phases 1-4 clinical trials of antibiotics, oncology and intensive care products for companies including Lederle (now Pfizer) and Centocor (now J&J), he spent five years managing sales and marketing for oncology and imaging products for Amersham International (now GE Healthcare). This led to 12 years as CEO for three UK biotech companies, Pharmagene, Paradigm Therapeutics and Stem Cell Sciences; in these roles he was the principal involved in an IPO on UK’s main list, trade sales to international companies in Japan and the USA and significant fund raising rounds. He has been Chairman of Silence Therapeutics (AIM listed) and Chairman of Definigen Ltd, a private Cambridge University spinout. He is currently on the Board of three biotechnology companies;  AzurRx Biotherapeutics, a New York based drug development company listed on NASDAQ; Cristal Therapeutics, a Netherlands based company specialising in nanoparticle medicines; and Skyline Vet Pharma, a US based private company repurposing human drugs for use in companion animals. He is also Chairman of the SWAHSN (South West Academic Health Science Network), which seeks to improve and sustain the healthcare provision in the south-west of England by linking innovation from industry, academia and the NHS. Dr Riddell is on the Remuneration committee.

Lindsay Melvin, Chief Financial Officer

Mr Melvin is a chartered accountant and brings 30 years of financial and business experience to Feedback. Most recently he was Chief Executive Officer of the Chartered Institute of Payroll Professionals (CIPP) for eight years until July 2016. CIPP was voted the UK’s best association in the 2016 Associations Excellence Awards and was also voted as one of the Sunday Times “Best 100 Not for Profit Organisations” in 2016. Previously, Mr Melvin held Director-level roles in small- to medium-sized public and private companies including Arthur Shaw & Co plc where he was Finance Director for six years. Mr Melvin started his career at Grant Thornton where he spent 11 years.

Tim Irish, Non-Executive Director

Tim has worked in the life sciences industry for 30 years. His career has spanned global health technology companies across Europe and North America, including GSK, GE and Philips - the latter two in senior positions responsible for medical imaging. Tim is a Professor of Practice at Kings College London and a board member of Bournemouth University. Tim joined the board of the National Institute for Health and Care Excellence (NICE) in April 2015 and became the Senior Independent Director in May 2017. Tim currently holds a number of non-executive positions in health and technology related entities..

Simon Sturge, Non-Executive Director

Mr Sturge joined Merck Healthcare in 2014 and is currently Chief Operating Officer and member of the Healthcare Executive Committee. He is an experienced healthcare executive in the UK and has built a very strong reputation not only in the biotechnology industry but also in the investment community. His experience includes eight years at Celltech, and he was the founder and CEO of RiboTargets which later reversed into Vernalis Plc. After serving as CEO of OctoPlus N.V. for two years, he became Senior Vice President of Boehringer Ingelheim’s Biopharmaceutical Business. Mr Sturge is a regular speaker at conferences including the World Economic Forum.

As of 11th July 2019

The Company’s issued share capital at the above date was 373,283,250 ordinary shares of 0.25 pence each. The percentage of shares not held in public hands and insofar as the Company is aware (as defined by AIM rule 26) was 30.71%.

Shareholders with more than 3% holding were:

SHAREHOLDER TOTAL INTEREST % ISSUED SHARED CAPITAL
Thomas Charlton 86,800,000 23.25%
Barclays Nominees 31,311,640 11.12%
Jonathan Cranston 33,750,000 9.04%
Hargreaves Lansdown Nominees 13,962,981 4.96%
University of Sussex 9,400,000 3.34%
 

 

Get in touch

 

We operate from Bourn, just outside Cambridge.

Grange Park
Broadway
Bourn
Cambridge CB23 2TA
United Kingdom

Tel +44 (0) 1954 718072

Nominated Advisor (NOMAD):
Allenby Capital Limited
5 St Helen’s place
London
EC3A 6AB

Brokers:
Allenby Capital Limited
5 St Helen’s place
London
EC3A 6AB

Peterhouse Corporate Finance Limited
3rd Floor
New London House
15 Eldon Street
London
EC2M 7LD

Registrars:
Share Registrars Ltd
The Courtyard
17 West Street
Farnham
Surrey
GU9 7DR

Auditor:
haysmacintyre
26 Red Lion Square
London
WC1R 4AG

Bankers:
Natwest Bank
Conqueror House,
Vision Park,
Cambridge
CB24 9NL

Columns Including FDBK

VIEW ALL

Market Reports Including FDBK

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use